Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Akebia Therapeutics
Age
18–55
Sex
MALE
Healthy volunteers
Accepted
You may be eligible if
Healthy male subjects 18 to 55 years of age with a body mass index between 18 and 30 kg/m2
Participants and their partners must use a highly effective form of contraception during the study and for 1 month following discharge from the Clinical Research Unit (CRU)
Subjects must discontinue all iron preparations for 14 days prior to study drug administration
You may not be if
Current or past history of cardiovascular, cerebrovascular, pulmonary, renal or liver disease
Positive serology results for HBsAg, HCV, and HIV at Screening
Renal impairment (estimated glomerular filtration rate (eGFR) of \<65mL/min)
Known active cancer (except non-melanoma skin cancer) or history of chemotherapy use within the previous 24 months
Current or past history of gastric or duodenal ulcers or other diseases of the GI tract (including gastric bypass surgeries) that could interfere with absorption of study drug
Subjects with a known history of smoking and/or have used nicotine or nicotine-containing products within the past 6 months
